super ace bonus
Former Manchester United man Jaap Stam has told the club letting Scott McTominay go was a “bad call” as he’s the type of high-impact player “you don’t want to lose”. McTominay had his best season in a United shirt last term. He bagged 10 goals and three assists in all competitions, which included seven Premier League goals, a tally only beaten by two Red Devils players. The Scotsman has since scored four goals and provided three assists in a Napoli shirt after a £25million move. Ex-United man Stam has told the club it was a poor decision to let him go, given the impact he had at Old Trafford and is now having in Italy. “Scott McTominay has been a very important influence at Manchester United even though he wasn’t a guaranteed starter,” Stam told SportLens . “He scored goals and had a big impact and those are the players you don’t want to lose as a football club. MORE ON MAN UTD FROM F365: 👉 Man Utd lucky to have only one clown in worst Premier League XI of weekend 👉 Owen slams ‘stupid’ Man Utd star in Bournemouth loss as he urges Amorim to get ‘brutal’ 👉 Man Utd swap deal given ‘OK’ with Old Trafford seen as ‘perfect destination’ for ex-Brighton star “Leaving might’ve been a good step for him, as is currently being discussed with Marcus Rashford, but he may well have wanted to stay. “He has been a very important player for Napoli and his confidence is growing because he is starting most games and overall I think selling him was a bad call at United. “Sometimes you have to make tough decisions as a club and I understand that, but I wouldn’t have been keen to sell McTominay.” It seems United may not have known what they had until they lost it, as they could do with a player like McTominay amid their poor run, which sees them 13th in the Premier League. READ MORE : Amorim sets ‘focus’ on ‘improving’ Rashford as he’s ready to ‘forget’ explosive interview by Man Utd forward
Washington Capitals (16-6-1, in the Metropolitan Division) vs. New Jersey Devils (16-8-2, in the Metropolitan Division) Newark, New Jersey; Saturday, 7 p.m. EST Devils -168, Capitals +142; over/under is 6 BOTTOM LINE: The New Jersey Devils host the Washington Capitals after the Capitals knocked off the New York Islanders 5-4 in overtime. New Jersey is 16-8-2 overall with a 4-1-2 record against the Metropolitan Division. The Devils are fifth in the league with 89 total goals (averaging 3.4 per game). Washington is 16-6-1 overall with a 6-4-0 record in Metropolitan Division games. The Capitals have a 5-2-1 record in games decided by one goal. Saturday's game is the fourth time these teams square off this season. The Devils won the last meeting 3-2. TOP PERFORMERS: Jesper Bratt has 10 goals and 19 assists for the Devils. Stefan Noesen has five goals and two assists over the last 10 games. Dylan Strome has eight goals and 26 assists for the Capitals. Connor McMichael has scored five goals and added four assists over the past 10 games. LAST 10 GAMES: Devils: 7-3-0, averaging 3.1 goals, five assists, four penalties and 10.3 penalty minutes while giving up 2.3 goals per game. Capitals: 7-2-1, averaging 4.4 goals, 7.2 assists, 3.9 penalties and 8.7 penalty minutes while giving up 2.5 goals per game. INJURIES: Devils: None listed. Capitals: None listed. ___ The Associated Press created this story using technology provided by and data from . The Associated Press
( MENAFN - GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Knee Osteoarthritis pipeline constitutes 50+ key companies continuously working towards developing 60+ Knee Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. “Knee Osteoarthritis Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market. Some of the key takeaways from the Knee Osteoarthritis Pipeline Report: Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years. Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years. In September 2024, Cytonics has announced the completion of subject enrollment for its Phase I clinical trial of CYT-108, a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor. The company initiated this Phase I trial in July, which is a first-in-human, multicenter, six-month, double-blind, randomized controlled trial (RCT) aimed at evaluating the safety and efficacy of CYT-108 in patients with unilateral, mild-to-moderate primary OA of the knee. In June 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV) , a clinical-stage company focused on macrophage reprogramming immunotherapy, announced a positive interim data update from a Phase I/II investigator-initiated clinical trial of Allocetra in patients with end-stage knee osteoarthritis who were candidates for knee replacement surgery. Knee Osteoarthritis Overview Knee osteoarthritis is a degenerative joint disease that occurs when the protective cartilage in the knee joint wears down over time. This leads to pain, stiffness, swelling, and reduced mobility. The condition is most common in older adults but can also affect younger individuals due to injury or genetic factors. Risk factors include age, obesity, previous knee injuries, and family history. Symptoms often worsen with activity and improve with rest. Treatment options include physical therapy, pain management with medications, lifestyle changes like weight loss, and in severe cases, surgical interventions such as knee replacement. Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment- Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include: M6495: Merck KGaA PPV 06: Peptinov LG00034053: LG Chem StroMel: Akan Bioscience TTAX03: BioTissue,Inc. EP-104IAR: Eupraxia Pharmaceuticals Inc. OLP 1002: OliPass Corporation JTA-004: Bone Therapeutics X 0002: Techfields Pharma Lorecivivint: Biosplice Therapeutics Knee Osteoarthritis Route of Administration Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Parenteral Intravenous Subcutaneous Topical Knee Osteoarthritis Molecule Type Knee Osteoarthritis Products have been categorized under various Molecule types, such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Knee Osteoarthritis Pipeline Therapeutics Assessment Knee Osteoarthritis Assessment by Product Type Knee Osteoarthritis By Stage and Product Type Knee Osteoarthritis Assessment by Route of Administration Knee Osteoarthritis By Stage and Route of Administration Knee Osteoarthritis Assessment by Molecule Type Knee Osteoarthritis by Stage and Molecule Type DelveInsight's Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies Some of the key companies in the Knee Osteoarthritis Therapeutics Market include: Key companies developing therapies for Knee Osteoarthritis are - Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others. Knee Osteoarthritis Pipeline Analysis: The Knee Osteoarthritis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment. Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies Knee Osteoarthritis Pipeline Market Drivers Increase in prevalence of Osteoarthritis, robust Knee Osteoarthritis Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market. Knee Osteoarthritis Pipeline Market Barriers However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth. Scope of Knee Osteoarthritis Pipeline Drug Insight Coverage: Global Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials Table of Contents 1. Knee Osteoarthritis Report Introduction 2. Knee Osteoarthritis Executive Summary 3. Knee Osteoarthritis Overview 4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment 5. Knee Osteoarthritis Pipeline Therapeutics 6. Knee Osteoarthritis Late Stage Products (Phase II/III) 7. Knee Osteoarthritis Mid Stage Products (Phase II) 8. Knee Osteoarthritis Early Stage Products (Phase I) 9. Knee Osteoarthritis Preclinical Stage Products 10. Knee Osteoarthritis Therapeutics Assessment 11. Knee Osteoarthritis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Knee Osteoarthritis Key Companies 14. Knee Osteoarthritis Key Products 15. Knee Osteoarthritis Unmet Needs 16 . Knee Osteoarthritis Market Drivers and Barriers 17. Knee Osteoarthritis Future Perspectives and Conclusion 18. Knee Osteoarthritis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. MENAFN23122024003238003268ID1109025408 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Wembanyama has 19 points, 7 rebounds and 6 blocks to lead Spurs to 96-87 win over NetsExclusive-Microsoft works to add non-OpenAI models into 365 Copilot products, sources say
COLUMBIA — A Hopkins couple have been arrested in the death of their 2-month-old son who investigators said was hospitalized with broken bones in October. The infant’s parents, Gladys Moreno and Nelson Rizo-Alvarez, were booked at the Richland County jail Dec. 20 on charges of homicide by child abuse. And they’re being held without the option to post bail, the county court clerk's office said. Moreno, 26, and Rizo-Alvarez, 29, were arrested a few months after their newborn child died at a local hospital on Oct. 28, the Richland County Sheriff’s Department said in a press release. The department said its investigation revealed that foul play was involved in the child’s death, and his injuries were because of “blunt force trauma.” Investigators said they also found that the state Department of Social Services had contact with Moreno when another child of hers was earlier hospitalized with broken bones. This fall, Moreno and Rizo-Alvarez had brought their newborn to the emergency room, saying the 2-month-old child had been suffering an upper respiratory infection and experienced a choking episode earlier in the day that caused him to go limp and turn blue, the sheriff’s department said in an incident report. It said initial hospital exams showed that the breaks to the child’s bones were “callused and healing over.” Because the report was redacted, it’s not clear how health care providers discovered these injuries. Moreno and Rizo-Alvarez apparently said they did not know how their baby got injured. But they said that, a week earlier, the infant’s car seat fell off a shopping cart while the child was still strapped in, according to the incident report. The couple told investigators the infant appeared to be all right, and they did not call 911. The incident involving Moreno’s other child fell under the jurisdiction of the West Columbia Police Department, the sheriff’s department. Details about this case were not immediately available. Besides Moreno and Rizo-Alvarez’s felony charges, they are also facing a hold order from the U.S. Immigration and Customs Enforcement, according to the court clerks. There is no schedule yet for their court appearance.